News

SITC 2024: Elucidating the Therapeutically Relevant Mechanisms of TROP2 in Breast Cancer

SITC 2024: Update on Use of HDAC Inhibitor Plus Nivolumab in Advanced Melanoma

SITC 2024: Adding IL-4 Inhibitor to PD-1 Inhibitor Therapy for ER-Positive Breast Cancer

New Application for Accelerated Approval for Dato-DXd in Advanced EGFR-Mutated NSCLC

SITC 2024: Addition of Radiotherapy to Immunotherapy in Advanced Merkel Cell Carcinoma

SITC 2024: CRISPR Editing Yields New B-Cell Strategies for Treating HER2-Positive Breast Cancer

SITC 2024: Comparing Types of Tumor Infiltrating Lymphocytes in Merkel Cell Carcinoma

SITC 2024: Novel Method to Predict, Assess Immunotherapy Efficacy in NSCLC

SITC 2024: Potential Biomarker of Disease Progression After Immunotherapy for Advanced Melanoma

SITC 2024: Overcoming PARP Inhibitor Resistance in BRCA1-Mutated Breast Cancer

SITC 2024: Updated Overall Survival From PERLA Trial in Metastatic Nonsquamous NSCLC

SITC 2024: Efficacy Outcomes With TIL Therapy for Advanced Melanoma

SITC 2024: Can Machine Learning Identify Treatment-Specific Outcomes and Biomarkers in NSCLC?

Radiotherapy Strategy for Enhancing Immunotherapy for Triple-Negative Breast Cancer

Is Immunotherapy Efficacious for Children and Adolescents With Melanoma?

Ivonescimab Plus Chemotherapy for Triple-Negative Breast Cancer

Relapse Patterns From Long-Term Subgroup Analysis of IMpower010

Using Machine Learning Model to Predict NSCLC Progression After Upfront Pembrolizumab

Combination Regimen vs Docetaxel in Advanced NSCLC

Perioperative Use of Ivonescimab in Resectable NSCLC

FDA Approves Tumor Treating Fields Therapy for Metastatic NSCLC

ASTRO 2024: Combination of High-Dose Radiotherapy and Immunotherapy for Metastatic NSCLC

Novel Monoclonal Antibody Under Study in Phase III Trial of Nonsquamous NSCLC

ASTRO 2024: French Trial of Radiotherapy Plus T-DXd in HER2-Positive Breast Cancer

ASTRO 2024: Role of Durvalumab With Radiotherapy for Some With Locally Advanced NSCLC

ESMO 2024: Long-Term Survival Update for INMC Pooled Analysis of Neoadjuvant Therapy in Melanoma

Neoadjuvant/Adjuvant Nivolumab With Chemotherapy Approved for Resectable NSCLC

ASCO Quality 2024: Benefits of Acupuncture in Treating Chemotherapy-Induced Peripheral Neuropathy

ESMO 2024: Hypomethylation Plus Immune Checkpoint Inhibition for Metastatic Melanoma

Can Tusamitamab Ravtansine Improve Survival in CEACAM5-High NSCLC?

ESMO 2024: Chemotherapy-Free Immunotherapy for Immunogenic Triple-Negative Breast Cancer

ESMO 2024: 10-Year Outcomes With Pembrolizumab vs Ipilimumab in Advanced Melanoma

ESMO 2024: Novel EGFR TKI After Amivantamab Therapy for Lung Cancer With EGFR Mutation

ESMO 2024: Supplementary Biomarker Analyses of DAISY Trial of T-DXd in Metastatic Breast Cancer

WCLC 2024: Adding JAK1 Inhibitor to Pembrolizumab in Metastatic PD-L1–Positive NSCLC

ESMO 2024: Adding SBRT to Immunotherapy and Chemotherapy in High-Risk Breast Cancer

Amivantamab Plus Chemotherapy Approved by FDA for NSCLC With Certain Genetic Mutations

ESMO 2024: Immune Checkpoint Inhibition Following Targeted Therapy for Advanced Melanoma